BASP1 and leukemia: Having identified the myristoylated N‐terminal BASP1 peptide as a reagent to selectively interfere with the viability of v‐myc‐transformed cells, we explored if Myr‐NT would also inhibit the growth of leukemia cells containing high levels of endogenous MYC (Nesbit et al., 1999; Valovka et al., 2013) (Fig. S4A).